 This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic study of PM01183 for patients with advanced solid tumors to identify the dose limiting toxicities DLTs, determine the maximum tolerated dose MTD and the recommended dose RD of PM01183 administered every three weeks intravenously i.v. over one hour to patients with advanced solid tumors and to preliminarily determine the pharmacokinetics of PM01183, to evaluate the antitumor activity of PM01183 and the safety and tolerability of PM01183. Besides this study will evaluate the pharmacogenomics in tumor samples and peripheral white blood cells PWBCs of patients exposed to PM01183 at the RD in order to assess potential markers of response andor resistance. 